Immunotherapy in microsatellite instability-high and microsatellite stable colorectal cancer
Colorectal cancer (CRC) is genetically heterogeneous, particularly with regard to microsatellite stability, which significantly impacts treatment outcomes. Immunotherapy has emerged as a cornerstone in treating CRC, especially for cases with high microsatellite instability (MSI-H). However, microsatellite stable (MSS) CRC, which comprises the majority of cases, presents challenges due to its lower mutational burden and the immunosuppressive nature of its tumor microenvironment. Current research focuses on combination therapies and improving immunomodulatory strategies, such as targeting immune-suppressive cells or factors within the tumor microenvironment, to enhance the effectiveness of immunotherapy for MSS CRC and identify effective biomarkers. In this review, we searched Web of Science, PubMed (MEDLINE), Google Scholar, Embase, Cochrane Library, Science Direct, Scopus, and Springer Link to identify relevant studies up to October 2024. This review addresses these gaps by evaluating contemporary therapeutic strategies for MSS and MSI-H CRC, focusing on combination approaches designed to augment the efficacy of immune checkpoint inhibitors.
Authors
- Jinmiao Wang (ORCID: https://orcid.org/0000-0003-2020-3799)
- Tianzuo Wang (ORCID: https://orcid.org/0000-0001-6221-8564)
- Xiao Hu (ORCID: https://orcid.org/0000-0001-7092-4127)
- Boshi Duan
- Shupei Li
- Xue Bai
- Tianyou Wang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Suizhou Central Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s12672-026-04936-y
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00